

## 6. References

1. Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. *J Clin Psychiatry* 2004; 65 Suppl 3: 27–37.
2. Weiss M, Murray C, Weiss G. Adults with attention-deficit–hyperactivity disorder: Current concepts. *Journal of Psychiatric Practice* 2002; 8: 99–111.
3. Lamberg L. ADHD often undiagnosed in adults. *JAMA* 2003; 290: 1565–1567.
4. Castellanos FX, Tannock R. Neuroscience of attention-deficit–hyperactivity disorder: The search for endophenotypes. *Nat Rev Neurosci* 2002; 3: 617–628.
5. Roth RM, Saykin AJ. Executive dysfunction in attention-deficit–hyperactivity disorder: Cognitive and neuroimaging findings. *Psychiatr Clin North Am* 2004; 27: 83–96.
6. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): Effects of ADHD and psychiatric comorbidity. *Am J Psychiatry* 1995; 152: 1652–1658.
7. Curran S, Fitzgerald M. Attention deficit hyperactivity disorder in the prison population. *Am J Psychiatry* 1999; 156: 1664–1665.
8. Rasmussen K, Almvik R, Levander S. Attention deficit hyperactivity disorder, reading disability, and personality disorders in a prison population. *J Am Acad Psychiatry Law* 2001; 29: 186–193.
9. Barkley RA. Major life activity and health outcomes associated with attention-deficit–hyperactivity disorder. *J Clin Psychiatry* 2002; 63 Suppl 12: 10–15.
10. Murphy KR, Barkley RA, Bush T. Young adults with attention deficit hyperactivity disorder: Subtype differences in comorbidity, educational, and clinical history. *J Nerv Ment Dis* 2002; 190: 147–157.
11. Bemporad JR. Aspects of psychotherapy with adults with attention deficit disorder. *Ann N Y Acad Sci* 2001; 931: 302–309.
12. Adler LA, Chua HC. Management of ADHD in adults. *J Clin Psychiatry* 2002; 63 Suppl 12: 29–35.
13. Biederman J, Faraone SV, Mick E, Spencer T, Wilens T, Kiely K, et al. High risk for attention deficit hyperactivity disorder among children of parents with childhood onset of the disorder: A pilot study. *Am J Psychiatry* 1995; 152: 431–435.
14. Faraone SV, Biederman J, Spencer T, Wilens T, Seidman LJ, Mick E, et al. Attention-deficit–hyperactivity disorder in adults: An overview. *Biol Psychiatry* 2000; 48: 9–20.
15. Bramble D. Psychostimulants and psychiatrists: The Trent adult psychiatry psychostimulant survey. *J Psychopharmacol* 2000; 14: 67–69.
16. Barkley RA. *Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment*. New York: The Guilford Press, 1990.
17. Roy-Byrne P, Scheele L, Brinkley J, Ward N, Wiatrak C, Russo J, et al. Adult attention-deficit hyperactivity disorder: Assessment guidelines based on clinical presentation to a specialty clinic. *Compr Psychiatry* 1997; 38: 133–140.
18. Murphy P, Schachar R. Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults. *Am J Psychiatry* 2000; 157: 1156–1159.
19. Mannuzza S, Klein RG, Klein DF, Bessler A, ShROUT P. Accuracy of adult recall of childhood attention deficit hyperactivity disorder. *Am J Psychiatry* 2002; 159: 1882–1888.
20. Zucker M, Morris MK, Ingram SM, Morris RD, Bakeman R. Concordance of self- and informant ratings of adults' current and childhood attention-deficit–hyperactivity disorder symptoms. *Psychol Assess* 2002; 14: 379–389.
21. Weiss M, Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. *CMAJ* 2003; 168: 715–722.

22. Stockl KM, Hughes TE, Jarrar MA, Secnik K, Perwien AR. Physician perceptions of the use of medications for attention deficit hyperactivity disorder. *J Manag Care Pharm* 2003; 9: 416–423.
23. Beck C, Silverstone P, Glor K, Dunn J. Psychostimulant prescriptions by psychiatrists higher than expected: A self-report survey. *Can J Psychiatry* 1999; 44: 680–684.
24. Biederman J, Faraone SV, Keenan K, Benjamin J, Krifcher B, Moore C, et al. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder: Patterns of comorbidity in probands and relatives in psychiatrically and pediatrically referred samples. *Arch Gen Psychiatry* 1992; 49: 728–738.
25. Levy F, Hay DA, McStephen M, Wood C, Waldman I. Attention-deficit hyperactivity disorder: A category or a continuum? Genetic analysis of a large-scale twin study. *J Am Acad Child Adolesc Psychiatry* 1997; 36: 737–744.
26. Epstein JN, Conners CK, Erhardt D, Arnold LE, Hechtman L, Hinshaw SP, et al. Familial aggregation of ADHD characteristics. *J Abnorm Child Psychol* 2000; 28: 585–594.
27. Spencer TJ, Biederman J, Wilens TE, Faraone SV. Overview and neurobiology of attention-deficit–hyperactivity disorder. *J Clin Psychiatry* 2002; 63 Suppl 12: 3–9.
28. Yeh M, Morley KI, Hall WD. The policy and ethical implications of genetic research on attention deficit hyperactivity disorder. *Aust N Z J Psychiatry* 2004; 38: 10–19.
29. American Academy of Child and Adolescent Psychiatry. Summary of the practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit–hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry* 1997; 36(10 Suppl).
30. Gallagher R, Blader J. The diagnosis and neuropsychological assessment of adult attention deficit–hyperactivity disorder. *Ann N Y Acad Sci* 2001; 931: 148–171.
31. Ward M, Wender P, Reimherr F. The Wender Utah Rating Scale: An aid to retrospective diagnosis of childhood attention deficit hyperactivity disorder. *Am J Psychiatry* 1993; 77: 751–754.
32. Conners CK, Erhardt D, Sparrow E. *Conners' Adult ADHD Rating Scales, Technical Manual*. New York: Multi-Health Systems, 1999.
33. Brown TE. *Brown Attention-Deficit Disorder Scales Manual*. San Antonio: The Psychological Corporation, 1996.
34. Giedd JN, Blumenthal J, Molloy E, Castellanos FX. Brain imaging of attention deficit–hyperactivity disorder. *Ann N Y Acad Sci* 2001; 931: 33–49.
35. Riccio CA, Reynolds CR. Continuous performance tests are sensitive to ADHD in adults but lack specificity. *Ann N Y Acad Sci* 2001; 931:113–139.
36. Elliott H. Attention deficit hyperactivity disorder in adults: A guide for the primary care physician. *South Med J* 2002; 95: 736–742.
37. National Health and Medical Research Council. *Attention Deficit Hyperactivity Disorder*. Canberra: Commonwealth Department of Health and Family Services, 1997. Available online from [www.nhmrc.gov.au/publications/adhd/contents.htm](http://www.nhmrc.gov.au/publications/adhd/contents.htm).
38. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)*. Washington, DC: American Psychiatric Association, 1994.
39. Murphy KR, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: Implications for clinical diagnosis. *J Atten Disord* 1996; 1: 147–161.
40. Marks DJ, Newcorn JH, Halperin JM. Comorbidity in adults with attention-deficit–hyperactivity disorder. *Ann N Y Acad Sci* 2001; 931: 216–238.
41. Hesslinger B, Tebartz van Elst L, Mochan F, Ebert D. A psychopathological study into the relationship between attention deficit hyperactivity disorder in adult patients and recurrent brief depression. *Acta Psychiatr Scand* 2003; 107: 385–389.

42. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: Impact of remission definition and symptom type. *Am J Psychiatry* 2000; 157: 816–818.
43. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult psychiatric status of hyperactive boys grown up. *Am J Psychiatry* 1998; 155: 493–498.
44. Weiss M, Hechtman LT. *Hyperactive children grown up, 2nd edition*. New York: The Guilford Press, 1993.
45. Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit–hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. *J Abnorm Psychol* 2002; 111: 279–289.
46. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: Antisocial activities and drug use. *Journal of Child Psychology and Psychiatry* 2004; 45: 195–211.
47. Arnold LE. Sex differences in ADHD: Conference summary. *J Abnorm Child Psychol* 1996; 42: 555–569.
48. Hermens D, Williams LM, Lazzaro I, Whitmont S, Melkonian D, Gordon E. Sex differences in adult ADHD: A double dissociation in brain activity and autonomic arousal. Available online from [www.brain-dynamics.net/braindynamics/publications/pub\\_files/Hermens\\_03\\_adultADHD.pdf](http://www.brain-dynamics.net/braindynamics/publications/pub_files/Hermens_03_adultADHD.pdf).
49. Seidman LJ, Valera EM, Bush G. Brain function and structure in adults with attention-deficit–hyperactivity disorder. *Psychiatr Clin North Am* 2004; 27: 323–347.
50. National Resource Centre on ADHD. *AD–HD in women*. Information and Resource Sheet No. 10, 2004. Available online from [www.help4adhd.org/en/living/womengirls/adhdinwomen](http://www.help4adhd.org/en/living/womengirls/adhdinwomen).
51. Biederman J, Faraone SV, Spencer T, Wilens T, Mick E, Lapey KA. Gender differences in a sample of adults with attention deficit hyperactivity disorder. *Psychiatry Res* 1994; 53: 13–29.
52. Safer DJ, Zito JM, Fine E. Increased methylphenidate usage for attention deficit disorder in the 1990s. *Pediatrics* 1996; 98: 1084–1088.
53. Rushton JL, Whitmire JT. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998. *Arch Pediatr Adolesc Med* 2001; 155: 560–565.
54. Berbatis CG, Sunderland VB, Bulsara M. Licit psychostimulant consumption in Australia, 1984–2000: International and jurisdictional comparison. *MJA* 2002; 177: 539–543.
55. Salmelainen P. *Trends in the prescribing of stimulant medication for the treatment of Attention Deficit Hyperactivity Disorder in NSW*. Sydney: NSW Department of Health, 2002. Available online from [www.health.nsw.gov.au/public-health/phb/phb.html](http://www.health.nsw.gov.au/public-health/phb/phb.html).
56. Rappley MD, Gardiner JC, Jetton JR, Houang RT. The use of methylphenidate in Michigan. *Arch Pediatr Adolesc Med* 1995; 149: 675–679.
57. Prosser B, Reid R. Psychostimulant use for children with ADHD in Australia. *Journal of Emotional and Behavioral Disorders* 1999; 7: 110–117.
58. Hoagwood K, Jensen PS, Feil M, Vitiello B, Bhatara VS. Medication management of stimulants in pediatric practice settings: A national perspective. *Developmental and Behavioral Pediatrics* 2000; 21: 322–331.
59. Miller AR, Lalonde CE, McGrail KM, Armstrong RW. Prescription of methylphenidate to children and youth. *CMAJ* 2001; 165: 1489–1494.
60. Reid R, Hakendorf P, Prosser B. Use of psychostimulant medication for ADHD in South Australia. *J Am Acad Child Adolesc Psychiatry* 2002; 41: 906–913.
61. Efron D, Hiscock H, Sewell JR, Cranswick NE, Vance ALA, Tyl Y, et al. Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. *Pediatrics* 2003; 111: 372–375.
62. Reed E, Vance A, Luk E, Nunn K. Single and combined psychotropic medication use in a child and adolescent mental health service. *Aust N Z J Psychiatry* 2004; 38: 204–211.

63. Biederman J, Spencer T. Methylphenidate in treatment of adults with attention-deficit-hyperactivity disorder. *J Atten Disord* 2002; 6(Suppl 1): s101–s107.
64. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit-hyperactivity disorder. *J Atten Disord* 2002; 5: 189–202.
65. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit-hyperactivity disorder. *J Clin Psychopharmacol* 2004; 24: 24–29.
66. Paterson R, Douglas C, Hallmayer J, Hagan M, Krupenia Z. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. *Aust N Z J Psychiatry* 1999; 33: 494–502.
67. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit-hyperactivity disorder. *J Clin Psychopharmacol* 2001; 21: 223–228.
68. Spear J, Alderton D. Psychosis associated with prescribed dexamphetamine use. *Aust N Z J Psychiatry* 2003; 37: 383.
69. American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. *J Am Acad Child Adolesc Psychiatry* 2002; 41(2 Suppl): s26–s49.
70. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. *Am J Psychiatry* 2003; 160: 1909–1918.
71. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of attention-deficit-hyperactivity disorder reduces risk for substance use disorder. *Pediatrics* 1999; 104(2). Available online from [www.pediatrics.org/cgi/content/full/104/2/e20](http://www.pediatrics.org/cgi/content/full/104/2/e20).
72. Fischer M, Barkley RA. Childhood stimulant treatment and risk for later substance abuse. *J Clin Psychiatry* 2003; 64(Suppl 11): 19–23.
73. Higgins ES. ADHD and substance abuse: 4 therapeutic options for patients with addictions. *Current Psychiatry Online* 2002; 1(11). Available online from [www.currentpsychiatry.com/2002\\_11/1102\\_adhd.asp](http://www.currentpsychiatry.com/2002_11/1102_adhd.asp).
74. Levin FR. Substance abuse and adult ADHD. *Psychiatric Times* 2000;17(2). Available online from [www.psychiatristimes.com/p000260.html](http://www.psychiatristimes.com/p000260.html).
75. Coetzee M, Kaminer Y, Morales A. Megadose intranasal methylphenidate (ritalin) abuse in adult attention deficit hyperactivity disorder. *Subst Abuse* 2002; 23: 165–169.
76. Biederman J. Practical considerations in stimulant drug selection for the attention-deficit-hyperactivity disorder patient—Efficacy, potency and titration. *Today's Therapeutic Trends* 2002; 20: 311–328.
77. Higgins ES. A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder. *J Fam Pract* 1999; 48: 15–20.
78. Kuperman S, Perry PJ, Gaffney GR, Lund BC, Bever-Stille KA, Arndt S, et al. Bupropion SR versus methylphenidate versus placebo for attention deficit hyperactivity disorder in adults. *Ann Clin Psychiatry* 2001; 13: 129–134.
79. United States Department of Health, Education, and Welfare. *ECDEU assessment manual for psychopharmacology. Clinical Global Impressions Scale*. Rockville: National Institute for Mental Health, 1976. Publication no. ADM76–338.
80. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. *Am J Psychiatry* 2002; 159: 1896–1901.
81. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. *Biol Psychiatry* 2003; 53: 112–120.
82. Adler L, Spencer T, Michelson D, Jones D, Milton D. Long-term treatment effects of atomoxetine in adults with attention-deficit-hyperactivity disorder. Presented at 16th ECNP Congress, 2003, September 20–24, Prague.

83. Adler L, Kelsey D, Dietrich AP, Reimherr FW, Sangal BR, Saylor KE, et al. Quality-of-life assessment in atomoxetine-treated adult ADHD patients. Presented at American Psychiatric Association, 2004, May 1–6, New York.
84. Buck ML. Atomoxetine: A new alternative for the treatment of attention-deficit-hyperactivity disorder. *Pediatric Pharmacotherapy* 2003; 9(4). Available online from [www.hsc.virginia.edu/medicine/clinical/pediatrics/CMC/pedpharm/pedpharm.html](http://www.hsc.virginia.edu/medicine/clinical/pediatrics/CMC/pedpharm/pedpharm.html).
85. Stevenson CS, Whitmont S, Bornholt L, Livesey D, Stevenson RJ. A cognitive remediation programme for adults with attention deficit hyperactivity disorder. *Aust N Z J Psychiatry* 2002; 36: 610–616.
86. Arnold LE. Alternative treatments for adults with attention-deficit hyperactivity disorder (ADHD). *Ann N Y Acad Sci* 2001; 931: 310–341.
87. Children and Adults with Attention-Deficit/Hyperactivity Disorder. *Assessing complementary and controversial interventions*. CHADD Fact Sheet No.6. Available online from [www.chadd.org](http://www.chadd.org).
88. NSW Department of Health. *Criteria for the diagnosis and management of attention deficit hyperactivity disorder in adults*. Sydney: NSW Department of Health, 2003. Publication no. TG 190/3. Available online from [www.health.nsw.gov.au/public-health/psb/publications/pdf/adhd\\_criteria\\_adult.pdf](http://www.health.nsw.gov.au/public-health/psb/publications/pdf/adhd_criteria_adult.pdf).
89. NSW Department of Health. *Criteria for the diagnosis and management of attention deficit hyperactivity disorder in children and adolescents*. Sydney: NSW Department of Health, 2004. Publication no. TG 181/6. Available online from [www.health.nsw.gov.au/public-health/psb/publications/pdf/adhd\\_criteria\\_child.pdf](http://www.health.nsw.gov.au/public-health/psb/publications/pdf/adhd_criteria_child.pdf).
90. Australian Bureau of Statistics. *Population by Sex and Age, States and Territories of Australia*. Catalogue no. 3201.0. Canberra: ABS, 1993–2003.
91. Australian Bureau of Statistics. *Estimated Resident Population by Sex and Age, 30 June 2001* (unpublished data). Centre for Epidemiology and Research, NSW Department of Health, 2004.
92. Derogatis LR. *SCL-90-R: Administration, scoring and procedures manual, 2nd edition*. Towson, MD: Clinical Psychometric Research Inc, 1992.
93. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psych* 1961; 4: 53–63.
94. Adler LA. Clinical presentations of adult patients with ADHD. *J Clin Psychiatry* 2004; 65(Suppl 3): 8–11.